This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CYTH Cyclo Therapeutics (CYTH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Cyclo Therapeutics Stock (NASDAQ:CYTH) 30 days 90 days 365 days Advanced Chart Get Cyclo Therapeutics alerts:Sign Up Key Stats Today's Range$0.72▼$0.7250-Day Range$0.72▼$0.7252-Week Range$0.55▼$1.45VolumeN/AAverage Volume585,177 shsMarket Capitalization$23.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida. Read More Receive CYTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYTH Stock News HeadlinesCyclo Therapeutics shareholders approve merger with Rafael HoldingsMarch 26, 2025 | uk.investing.comIs Cyclo Therapeutics, Inc. (CYTH) the Best Micro Cap Stock to Buy Now?March 7, 2025 | insidermonkey.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account. | Weiss Ratings (Ad)10 Best Micro Cap Stocks to Buy NowMarch 6, 2025 | insidermonkey.comCYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTHFebruary 20, 2025 | businesswire.comCyclo Therapeutics reports promising NPC1 treatment findingsFebruary 7, 2025 | msn.comCyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)February 7, 2025 | businesswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATSG, CYTH, ALVR on Behalf of ShareholdersJanuary 24, 2025 | stockhouse.comSee More Headlines CYTH Stock Analysis - Frequently Asked Questions How were Cyclo Therapeutics' earnings last quarter? Cyclo Therapeutics, Inc. (NASDAQ:CYTH) posted its quarterly earnings data on Thursday, August, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.07. The firm had revenue of $0.12 million for the quarter, compared to analysts' expectations of $0.40 million. What other stocks do shareholders of Cyclo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclo Therapeutics investors own include Rolls-Royce Holdings PLC (RYCEY), Blink Charging (BLNK), Ford Motor (F), Alphabet (GOOG), Cassava Sciences (SAVA), Zoom Communications (ZM) and Fisker (FSR). Company Calendar Last Earnings8/15/2024Today9/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYTH CIK922247 Webwww.ctd-holdings.com Phone(386) 418-8060Fax321-244-8351Employees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.06 million Net Margins-2,847.19% Pretax Margin-2,847.30% Return on EquityN/A Return on Assets-307.16% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.16 Sales & Book Value Annual Sales$870.73 thousand Price / Sales27.24 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book3.43Miscellaneous Outstanding Shares32,919,000Free Float23,116,000Market Cap$23.72 million OptionableNo Data Beta-0.57 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CYTH) was last updated on 9/8/2025 by MarketBeat.com Staff From Our PartnersThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.